KREBSBIO

Krebs Biochemicals and Industries Limited

Fermentation-based Active Pharmaceutical Ingredients and drug intermediates

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

krebsbiochem.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-19

Stock price
₹57.88
Market cap
125 Cr
Stock P/E
Loss (TTM EPS ₹-6.52)
ROCE (FY26)
-19.1%
Operating margin (FY26)
-50.0%
Debt / equity (FY26)
-0.01

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Krebs Biochemicals makes fermentation-based active pharmaceutical ingredients (APIs, the active drug substances in medicines) and drug intermediates, including an API used in the largest-selling formulation of Ipca Laboratories.

Company snapshot

110thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Debt-to-equity of -0.01x — the company is largely funded by its own money, not borrowed funds.
Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
1 more signal from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales15 Cr13 Cr12 Cr13 Cr13 Cr11 Cr6 Cr5 Cr4 Cr7 Cr7 Cr7 Cr
Operating expenses (approx.)16 Cr15 Cr15 Cr15 Cr16 Cr16 Cr12 Cr8 Cr7 Cr7 Cr8 Cr6 Cr
EBITDA-0.90 Cr-2 Cr-3 Cr-2 Cr-3 Cr-5 Cr-5 Cr-2 Cr-3 Cr0.30 Cr-0.87 Cr0.83 Cr
OPM %-6.0%-16.1%-26.0%-17.0%-21.1%-41.1%-88.6%-38.1%-67.0%4.1%-12.7%11.8%
Other income0.17 Cr0.03 Cr0.21 Cr0.03 Cr0.09 Cr0.25 Cr0.34 Cr0.01 Cr0.0067 Cr0.0043 Cr2 Cr0.16 Cr
Interest1 Cr1 Cr1 Cr1 Cr1 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr
Depreciation2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr
Profit before tax-4 Cr-5 Cr-6 Cr-5 Cr-6 Cr-8 Cr-8 Cr-5 Cr-6 Cr-3 Cr-2 Cr-2 Cr
Tax %0.0%0.0%0.0%0.0%0.0%0.0%-0.2%0.0%0.0%0.0%0.0%0.0%
Net profit-4 Cr-5 Cr-6 Cr-5 Cr-6 Cr-8 Cr-8 Cr-5 Cr-6 Cr-3 Cr-2 Cr-2 Cr
EPS (₹)₹-1.66₹-2.31₹-2.72₹-2.40₹-2.67₹-3.59₹-3.83₹-2.47₹-2.85₹-1.45₹-1.09₹-1.15

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales—34 Cr48 Cr33 Cr54 Cr53 Cr52 Cr50 Cr43 Cr24 CrSign in free for the trailing twelve months
Operating expenses (approx.)—41 Cr58 Cr52 Cr71 Cr94 Cr68 Cr59 Cr58 Cr29 CrSign in free for the trailing twelve months
EBITDA—-8 Cr-10 Cr-19 Cr-18 Cr-41 Cr-16 Cr-9 Cr-15 Cr-5 CrSign in free for the trailing twelve months
OPM %—-22.2%-20.5%-55.8%-32.7%-77.0%-30.3%-17.3%-34.7%-23.0%Sign in free for the trailing twelve months
Other income—0.21 Cr0.33 Cr0.37 Cr0.62 Cr8 Cr0.62 Cr0.45 Cr0.71 Cr2 CrSign in free for the trailing twelve months
Interest—5 Cr6 Cr6 Cr6 Cr5 Cr3 Cr5 Cr6 Cr7 CrSign in free for the trailing twelve months
Depreciation—4 Cr4 Cr5 Cr5 Cr6 Cr7 Cr7 Cr7 Cr6 CrSign in free for the trailing twelve months
Profit before tax—-18 Cr-20 Cr-29 Cr-28 Cr-45 Cr-25 Cr-20 Cr-27 Cr-17 CrSign in free for the trailing twelve months
Tax %—0.0%0.0%0.0%0.0%0.0%0.0%0.0%-0.1%0.0%Sign in free for the trailing twelve months
Net profit—-18 Cr-20 Cr-29 Cr-28 Cr-45 Cr-25 Cr-20 Cr-27 Cr-17 CrSign in free for the trailing twelve months
EPS (₹)—₹-14.01₹-12.83₹-16.75₹-14.53₹-20.81₹-11.30₹-9.16₹-12.49₹-7.85Sign in free for the trailing twelve months
Dividend payout %——————————Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital14 Cr14 Cr17 Cr18 Cr20 Cr22 Cr22 Cr22 Cr22 Cr22 Cr
Reserves-12 Cr-32 Cr-31 Cr-43 Cr-62 Cr-97 Cr-121 Cr-141 Cr-168 Cr-184 Cr
Borrowings43 Cr52 Cr50 Cr66 Cr101 Cr143 Cr183 Cr193 Cr212 Cr225 Cr
Other liabilities78 Cr92 Cr106 Cr93 Cr101 Cr122 Cr91 Cr104 Cr103 Cr101 Cr
Total liabilities122 Cr126 Cr142 Cr134 Cr159 Cr190 Cr175 Cr178 Cr169 Cr163 Cr
Fixed assets (net)99 Cr99 Cr99 Cr103 Cr116 Cr138 Cr146 Cr149 Cr145 Cr141 Cr
CWIP4 Cr2 Cr2 Cr2 Cr10 Cr7 Cr2 Cr0.16 Cr1 Cr2 Cr
Investments——0 Cr0 Cr0 Cr0 Cr0 Cr0 Cr0 Cr0 Cr
Loans & advances——0 Cr0 Cr0 Cr0 Cr0 Cr3 Cr0.20 Cr0.18 Cr
Inventories5 Cr12 Cr9 Cr15 Cr17 Cr26 Cr12 Cr10 Cr6 Cr6 Cr
Trade receivables2 Cr0.32 Cr3 Cr0.20 Cr0.30 Cr0.88 Cr0.53 Cr2 Cr0.05 Cr0.0043 Cr
Cash & bank0.12 Cr0.42 Cr17 Cr0.17 Cr0.71 Cr0.10 Cr0.09 Cr0.14 Cr0.14 Cr0.13 Cr
Other assets13 Cr12 Cr12 Cr13 Cr15 Cr19 Cr14 Cr14 Cr16 Cr14 Cr
Total assets122 Cr126 Cr142 Cr134 Cr159 Cr190 Cr175 Cr178 Cr169 Cr163 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity-11 Cr-7 Cr4 Cr-36 Cr-12 Cr-17 Cr-26 Cr2 Cr-8 Cr-2 Cr
Cash from investing-5 Cr-1 Cr-4 Cr-9 Cr-26 Cr-23 Cr-11 Cr-8 Cr-5 Cr-4 Cr
Cash from financing16 Cr9 Cr17 Cr28 Cr38 Cr40 Cr37 Cr6 Cr13 Cr6 Cr
Net cash flow-0.15 Cr0.30 Cr17 Cr-17 Cr0.54 Cr-0.61 Cr-0.01 Cr0.05 Cr0.0042 Cr-0.01 Cr
Free cash flow (OCF − Capex)-17 Cr-10 Cr-0.75 Cr-45 Cr-37 Cr-44 Cr-37 Cr-6 Cr-13 Cr-6 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %——-39.6%-57.5%-39.3%-69.4%-26.7%-20.9%-32.9%-19.1%
ROE %——————————
Debtor days—42222641400
Inventory days—24915528523620128365888141111
Days payable—3783724322952993621275265199169
Cash conversion cycle—-125-195-144-57-91-75-603-1769-58058
Debt / equity28.97—-0.04———-0.02-0.02-0.01-0.01
Current ratio0.410.380.560.440.440.450.330.280.100.09
Net debt / EBITDA——————————